Dycom Industries Free cash flow decreased by 126.0% to -$94.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 28.9%, from -$133.47M to -$94.90M. Over 3 years (FY 2022 to FY 2026), Free cash flow shows an upward trend with a 38.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | Q1 '27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $9.88M | -$19.43M | $59.18M | $101.98M | -$103.32M | -$54.56M | -$59.35M | -$128.04M | $5.30M | -$104.51M | $267.73M | -$79.36M | -$72.94M | -$8.79M | $259.73M | -$133.47M | $5.76M | $164.81M | $364.61M | -$94.90M |
| QoQ Change | — | -296.6% | +404.6% | +72.3% | -201.3% | +47.2% | -8.8% | -115.7% | +104.1% | <-999% | +356.2% | -129.6% | +8.1% | +88.0% | >999% | -151.4% | +104.3% | >999% | +121.2% | -126.0% |
| YoY Change | — | — | — | — | <-999% | -180.8% | -200.3% | -23.9% | +109.7% | -76.1% | — | +38.0% | <-999% | +91.6% | -3.0% | -68.2% | +107.9% | >999% | +40.4% | +28.9% |